A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials

BACKGROUND: Combinations of drugs are becoming increasingly common in oncology treatment. In some cases, patients can benefit from the interaction between two drugs, although there is usually a higher risk of developing toxicity. Due to drug–drug interactions, multidrug combinations often exhibit di...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhaohang, Xu, Ze, Zhang, Aijun, Qi, Guanpeng, Li, Zuojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979534/
https://www.ncbi.nlm.nih.gov/pubmed/36864387
http://dx.doi.org/10.1186/s12874-023-01867-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979534/
https://www.ncbi.nlm.nih.gov/pubmed/36864387
http://dx.doi.org/10.1186/s12874-023-01867-y

Ejemplares similares